AFA
NBIX icon

Abacus FCF Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Abacus FCF Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,574
Closed -$1.22M – 294
2024
Q3 		$1.22M Sell
10,574
-463
-4% -$63.5K 0.28% 121
2024
Q2 		$1.52M Buy
+11,037
New +$1.51M 0.38% 104
2024
Q1 		– Sell
-8,783
Closed -$1.16M – 157
2023
Q4 		$1.16M Buy
+8,783
New +$1.01M 0.34% 102

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abacus FCF Advisors's NBIX Position: Q4 2024 in Review

Abacus FCF Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 10,574 shares — an estimated $1.22M sold.

Abacus FCF Advisors first reported a position in NBIX in Q4 2023 and held it in 3 quarters. The position peaked at $1.52M in Q2 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Abacus FCF Advisors reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Abacus FCF Advisors sold 10,574 Neurocrine Biosciences shares in Q4 2024, an estimated $1.22M.
  • Abacus FCF Advisors first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 3 quarters.
  • Abacus FCF Advisors's Neurocrine Biosciences position peaked at $1.52M in Q2 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Abacus FCF Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.